BioMimetix Announces Publication of Phase I/II Clinical Trial Evaluating BMX-001 in Patients With Locally Advanced Head and Neck Cancer

On November 19, 2026 BioMimetix JV, LLC reported the publication of results from a NCI funded multicenter Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study found that BMX-001 was safe and well tolerated and suggested substantial efficacy in mitigating treatment-related toxicities, including oral mucositis, xerostomia, and radiation dermatitis, in patients who received standard of care chemoradiation.

The results have been published in the International Journal of Radiation Oncology, Biology, Physics.

"The reduction of treatment-related toxicities is a major and elusive challenge in the management of head and neck cancer," said David M. Brizel, MD, Principal Investigator of the study. "These findings suggest that BMX-001 will reduce the severity of these toxicities while maintaining the effectiveness of chemoradiation therapy."

Key Study Findings
This single-arm Phase I/II study enrolled 29 patients with stage III–IV head and neck squamous cell carcinoma who received the investigational drug, BMX-001, in combination with chemoradiation therapy.

Key results included:

Favorable safety profile, with only one patient experiencing serious adverse events possibly related to BMX-001
No Grade 4 cases of severe oral mucositis were observed. Grade 3 severe oral mucositis was delayed in onset and occurred in only 41.4% of patients
Rates of xerostomia were low, with long term Grade ≥ 2 events occurring in only 9.1% of subjects
At a median follow-up of 24 months, 96.6% of patients were alive without disease progression
Administration of BMX-001 showed a profound positive impact on quality of life with many measures returning to baseline by six months.
Study Background
Radiation therapy and chemotherapy induce oxidative stress that contributes to treatment-related toxicities such as oral mucositis and xerostomia which significantly impair patients’ quality of life and treatment adherence.

BMX-001 is a redox-active superoxide dismutase mimic that down-regulates oxidative stress pathways associated with radiation therapy, while stimulating repair pathways. These same impacts of BMX-001 inhibit tumor cell growth because of the unique metabolic pathways active in tumors. Preclinical studies show that BMX-001 protects normal tissues from radiation-induced injury while enhancing tumor responses to treatment.

This study represents a multi-institutional Phase I/II clinical trial of BMX-001 evaluating its safety, tolerability and efficacy in patients receiving concurrent chemoradiation for head and neck cancer.

Continued Development
"These results support the continued development of BMX-001 as a therapy to improve the efficacy and tolerability of radiation therapy in many different solid tumors," said James Crapo, MD CEO of BioMimetix. "Reducing treatment-related toxicities while preserving anti-tumor efficacy represent a unique and important step that will improve outcomes for patients with head and neck cancer."

BMX-001 is being investigated in additional clinical studies across multiple cancer types. BMX-001 is currently being evaluated in a randomized Phase II clinical trial (NRG-CC013; ClinicalTrials.gov Identifier: NCT06532279) conducted through the National Cancer Institute – supported by NRG Oncology, a Network Group in the NCI National Clinical Trials Network, to further assess its potential to reduce treatment-related toxicities in patients receiving chemoradiation for head and neck cancer.

About BMX-001
BMX-001 (MnTnBuOE-2-PyP⁵⁺) is a redox-active manganese metalloporphyrin compound that mimics the activity of superoxide dismutase enzymes and modulates oxidative stress pathways such as NFkB and HIF-1a. The compound has demonstrated potential to protect normal tissues from radiation-induced injury while maintaining or enhancing tumor response to radiation therapy with or without chemotherapy.

(Press release, BioMimetix Pharmaceutical, NOV 19, 2026, View Source [SID1234675005])